Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (411-420 of 743) with videos related to

Pageof 75
Sort By:
Pigment Cell & Melanoma Research|December 11, 2008
Novel MITF targets identified using a two-step DNA microarray strategyKeith S Hoek, Natalie C Schlegel, Ossia M Eichhoff, et al.
European Journal of Dermatology : EJD|April 15, 2011
Spitzoid melanoma and micrometastases in two lymph node regions: a critical situationAlexander A Navarini, Jürgen Bauer, Marjam J Barysch, et al.
Cancers|August 26, 2022
Targeted Long-Read Bisulfite Sequencing Identifies Differences in the <i>TERT</i> Promoter Methylation Profiles between <i>TERT</i> Wild-Type and <i>TERT</i> Mutant Cancer CellsSeungjae Lee, Ti-Cheng Chang, Patrick Schreiner, et al.
Pigment Cell & Melanoma Research|November 6, 2025
Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant MelanomaFlavia L Tellenbach, Luzia Seiler, Mark Johnson, et al.
Nature Communications|December 31, 2024
Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3<sup>+</sup> T<sub>reg</sub> populationStefan Wolf, Matiar Madanchi, Patrick Turko, et al.
Diagnostics (Basel, Switzerland)|June 2, 2021
Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma PatientsKen Kudura, Florentia Dimitriou, Daniela Mihic-Probst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012Reinhard Dummer, Pietro Quaglino, Jürgen C Becker, et al.
JID Innovations : Skin Science From Molecules to Population Health|January 27, 2025
DNA Methyltransferase Inhibition Upregulates the Costimulatory Molecule ICAM-1 and the Immunogenic Phenotype of Melanoma CellsAlessandra S P Cereghetti, Patrick Turko, Phil Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasisAxel Hauschild, Michael Weichenthal, Bernd-Rudiger Balda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanomaReinhard Dummer, Axel Hauschild, Juergen C Becker, et al.
Pageof 75

Showing results (411-420 of 743) with videos related to

Sort By:
Pageof 75
Pigment Cell & Melanoma Research|December 11, 2008
Novel MITF targets identified using a two-step DNA microarray strategyKeith S Hoek, Natalie C Schlegel, Ossia M Eichhoff, et al.
European Journal of Dermatology : EJD|April 15, 2011
Spitzoid melanoma and micrometastases in two lymph node regions: a critical situationAlexander A Navarini, Jürgen Bauer, Marjam J Barysch, et al.
Cancers|August 26, 2022
Targeted Long-Read Bisulfite Sequencing Identifies Differences in the <i>TERT</i> Promoter Methylation Profiles between <i>TERT</i> Wild-Type and <i>TERT</i> Mutant Cancer CellsSeungjae Lee, Ti-Cheng Chang, Patrick Schreiner, et al.
Pigment Cell & Melanoma Research|November 6, 2025
Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant MelanomaFlavia L Tellenbach, Luzia Seiler, Mark Johnson, et al.
Nature Communications|December 31, 2024
Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3<sup>+</sup> T<sub>reg</sub> populationStefan Wolf, Matiar Madanchi, Patrick Turko, et al.
Diagnostics (Basel, Switzerland)|June 2, 2021
Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma PatientsKen Kudura, Florentia Dimitriou, Daniela Mihic-Probst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012Reinhard Dummer, Pietro Quaglino, Jürgen C Becker, et al.
JID Innovations : Skin Science From Molecules to Population Health|January 27, 2025
DNA Methyltransferase Inhibition Upregulates the Costimulatory Molecule ICAM-1 and the Immunogenic Phenotype of Melanoma CellsAlessandra S P Cereghetti, Patrick Turko, Phil Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasisAxel Hauschild, Michael Weichenthal, Bernd-Rudiger Balda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanomaReinhard Dummer, Axel Hauschild, Juergen C Becker, et al.
Pageof 75